Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/10/2026 ,inter alia, to consider and approve the raising of funds through the issuance of equity shares of our Company with a face value of ? 5 each ('Equity Shares') by way of a rights issue to its eligible equity shareholders ('Rights Issue').

Evonile Pharma Limited (formerly known as Novartis India Limited) October 05, 2026 BSE Limited The Secretary, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. BSE Scrip Code: 500672 Subject: Prior intimation of meeting of the Board of Directors of Evonile Pharma Limited (formerly known as Novartis India Limited) (“Company”) under Regulation 29(1)(d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”). Dear Sir/Madam, In accordance with Regulation 29(1)(d) of the Listing Regulations, it is hereby informed that a meeting of the Board of Directors of our Company is scheduled to be held on Thursday, October 08, 2026, to inter alia, consider raising of funds through the issuance of equity shares of our Company with a face value of ₹ 5 each (“Equity Shares”) by way of a rights issue to its eligible equity shareholders (“Rights Issue”). The proposed fund-raising will be undertaken on such terms and conditions as may be determined by the Board, subject to the receipt of all necessary regulatory, statutory and other applicable approvals. In furtherance to the Stock Exchange disclosure made on September 30, 2026, regarding the closure of Trading Window, it is hereby re-iterated that the trading window for dealing in the securities of the Company by the Designated Persons/ Insiders/ Connected Persons and their immediate relatives has been closed w.e.f. October 01, 2026, till 48 hours of the disclosure of the unaudited Financial Results of the Company for the quarter and nine months ended September 30, 2026, i.e. till November 05, 2026. Since the Board meeting for consideration of the agenda for Rights Issue and other relevant items falls within the already closed trading window period, no separate trading window is closed at this stage. This is for your information. Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in Evonile Pharma Limited (formerly known as Novartis India Limited) The above information will also be available on the Company’s website at www.nilpharma.co.in Kindly take the above on record. Thank you, Yours faithfully, For Evonile Pharma Limited (formerly known as Novartis India Limited) Chandni Maru Company Secretary and Compliance Officer M. No. A60291 Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in